The effect of ibrutinib on neutrophil and γδ T cell functions

References

• O’Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131(17):1910–1919.
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539–2549.
   PubMed Web of Science ®Google Scholar
• Borge M, Almejun MB, Podaza E, et al. Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. Haematologica. 2015;100(4):e140–2.
   PubMed Web of Science ®Google Scholar
• Colado A, Genoula M, Cougoule C, et al. Effect of the BTK inhibitor ibrutinib on macrophage- and gammadelta T cell-mediated response against Mycobacterium tuberculosis. Blood Cancer J. 2018;8(11):100.
   PubMedGoogle Scholar
• Fiorcari S, Maffei R, Audrito V, et al. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget. 2016;7(40):65968–65981.
   PubMedGoogle Scholar
• Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126(5):573–581.
   PubMed Web of Science ®Google Scholar
• Ball S, Vutthikraivit W, Maiti A, et al. Infection with ibrutinib in patients with chronic lymphocytic leukemia: how strong is the association? Eur J Haematol. 2018;101(3):418–420.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Hillmen P, Coutre S, et al. Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leukemia. 2018;18(10):648–657 e15.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. JCO. 2013;31(1):88–94.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–332.
   PubMed Web of Science ®Google Scholar
• Kao JP, Harootunian AT, Tsien RY. Photochemically generated cytosolic calcium pulses and their detection by fluo-3. J Biol Chem. 1989;264(14):8179–8184.
   PubMed Web of Science ®Google Scholar
• Keitelman IA, Sabbione F, Shiromizu CM, et al. short-term fever-range hyperthermia accelerates NETosis and reduces pro-inflammatory cytokine secretion by human neutrophils. Front Immunol. 2019;10:2374.
   PubMed Web of Science ®Google Scholar
• Ley K, Hoffman HM, Kubes P, et al. Neutrophils: new insights and open questions. Sci Immunol. 2018;3(30):eaat4579. 7
   PubMed Web of Science ®Google Scholar
• Fiedler K, Sindrilaru A, Terszowski G, et al. Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia. Blood. 2011;117(4):1329–1339.
   PubMed Web of Science ®Google Scholar
• Gómez-Gaviro MV, Domı́nguez-Jiménez C, Carretero JM, et al. Down-regulation of L-selectin expression in neutrophils by nonsteroidal anti-inflammatory drugs: role of intracellular ATP concentration. Blood. 2000;96(10):3592–3600.
   PubMed Web of Science ®Google Scholar
• Alexander SR, Kishimoto TK, Walcheck B. Effects of selective protein kinase C inhibitors on the proteolytic down-regulation of L-selectin from chemoattractant-activated neutrophils. J Leukoc Biol. 2000;67(3):415–422.
   PubMed Web of Science ®Google Scholar
• Manukyan G, Papajik T, Gajdos P, et al. Neutrophils in chronic lymphocytic leukemia are permanently activated and have functional defects. Oncotarget. 2017;8(49):84889–84901.
   PubMedGoogle Scholar
• Podaza E, Sabbione F, Risnik D, et al. Neutrophils from chronic lymphocytic leukemia patients exhibit an increased capacity to release extracellular traps (NETs). Cancer Immunol Immunother. 2017;66(1):77–89.
   PubMed Web of Science ®Google Scholar
• de Weerdt I, Hofland T, Lameris R, et al. Improving CLL Vgamma9Vdelta2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib. Blood. 2018;132(21):2260–2272.
   PubMed Web of Science ®Google Scholar
• Long M, Beckwith K, Do P, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Investig. 2017;127(8):3052–3064.
   PubMed Web of Science ®Google Scholar
• Griggio V, Vitale C, Todaro M, et al. Ibrutinib treatment mitigates phenotypic alterations of non-neoplastic immune cell compartments in chronic lymphocytic leukemia. ASH meeting Poster 4412. 2018;132(Supplement 1):4412–4412.
   Google Scholar
• Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213–2219.
   PubMed Web of Science ®Google Scholar
• Varikuti S, Volpedo G, Saljoughian N, et al. The potent ITK/BTK inhibitor ibrutinib is effective for the treatment of experimental visceral leishmaniasis caused by Leishmania donovani. J Infect Dis. 2019;219(4):599–608.
   PubMed Web of Science ®Google Scholar
• Blez D, Blaize M, Soussain C, et al. Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus. Haematologica. 2020;105(2):478–489.
   PubMed Web of Science ®Google Scholar
• Stadler N, Hasibeder A, Lopez PA, et al. The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation. Haematologica. 2017;102(5):e191–e194.
   PubMed Web of Science ®Google Scholar
• Roit FD, Engelberts PJ, Taylor RP, et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica. 2015;100(1):77–86.
   PubMed Web of Science ®Google Scholar
• Prezzo A, Cavaliere FM, Bilotta C, et al. Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment. Leuk Res. 2019;87:106233.
   PubMed Web of Science ®Google Scholar
• Florence JM, Krupa A, Booshehri LM, et al. Inhibiting Bruton’s tyrosine kinase rescues mice from lethal influenza-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2018;315(1):L52–L58.
   PubMed Web of Science ®Google Scholar
• de Porto AP, Liu Z, de Beer R, et al. Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia. Mol Med. 2019;25(1):3.
   PubMedGoogle Scholar
• Ito M, Shichita T, Okada M, et al. Bruton’s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat Commun. 2015;6(1):7360.
   PubMed Web of Science ®Google Scholar
• Bercusson A, Colley T, Shah A, et al. Ibrutinib blocks Btk-dependent NF-kB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis. Blood. 2018;132(18):1985–1988.
   PubMed Web of Science ®Google Scholar
• Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955–1959.
   PubMed Web of Science ®Google Scholar